The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D 4 (LTD 4)/platelet activating factor (PAF) receptor antagonists.

A Marfat,R Chambers,J Cheng,K Cooper,D Damon,J Delehunt,J Eggler,H Masamune,L Melvin,J Watson

doi:10.1016/0960-894x(95)00227-k

The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D 4 (LTD 4)/platelet activating factor (PAF) receptor antagonists.

A Marfat, R Chambers + Show 8 more

https://doi.org/10.1016/0960-894x(95)00227-k

Copy DOI

Export

Save

Cite

Journal: Bioorganic & Medicinal Chemistry Letters	Publication Date: Jul 1, 1995
Citations: 4

Affiliation: Pfizer (United States)

#Platelet Activating Factor #Receptor Antagonists #Platelet Activating Factor Receptor Antagonists #Platelet Activating Factor Receptor #Key Pharmacophores #Synthesis Of Compounds #Structural Pharmacophores #Active Leukotriene #Potent Platelet #Hybrid Compounds

Abstract
Full-Text
Similar Papers

Abstract

Listen

The combination of key structural pharmacophores found in known leukotriene D 4 (LTD 4) receptor antagonists with those of potent platelet activating factor (PAF) receptor antagonist UK-74,505 has led to the synthesis of hybrid compounds CP-96,021 and CP-96,486. These compounds represent the first known balanced, combined and orally active LTD 4/PAF receptor antagonists.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Bioorganic & Medicinal Chemistry Letters

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D 4 (LTD 4)/platelet activating factor (PAF) receptor antagonists.